c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, agenetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.

Biotechnology

Pharmaceutical

c-LEcta GmbH

Dr. Marc Struhalla

Kamila Rzeznicka

Patrick Hapke

Carsten Fietz

Nicole Albrecht

Dr. Michael Dirkmann

Christine Merten

Pierre Aldag

Tjebbe van der Meer

Heike Kutschke

Arlett Merkel

Raphael Gübeli

Andreas Vogel

Arnd Knoll

Mathias Bell

Andreas Buthe

Research and Development

Leadership Team

Sales and Business Development

Regulatory and Intellectual Property

Biopharma Innovation Team

Marketing and Communications

Quality Assurance and Control

Teams at c-LEcta GmbH